These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
423 related articles for article (PubMed ID: 30773340)
1. A Platform of Synthetic Lethal Gene Interaction Networks Reveals that the GNAQ Uveal Melanoma Oncogene Controls the Hippo Pathway through FAK. Feng X; Arang N; Rigiracciolo DC; Lee JS; Yeerna H; Wang Z; Lubrano S; Kishore A; Pachter JA; König GM; Maggiolini M; Kostenis E; Schlaepfer DD; Tamayo P; Chen Q; Ruppin E; Gutkind JS Cancer Cell; 2019 Mar; 35(3):457-472.e5. PubMed ID: 30773340 [TBL] [Abstract][Full Text] [Related]
2. Hippo-independent activation of YAP by the GNAQ uveal melanoma oncogene through a trio-regulated rho GTPase signaling circuitry. Feng X; Degese MS; Iglesias-Bartolome R; Vaque JP; Molinolo AA; Rodrigues M; Zaidi MR; Ksander BR; Merlino G; Sodhi A; Chen Q; Gutkind JS Cancer Cell; 2014 Jun; 25(6):831-45. PubMed ID: 24882515 [TBL] [Abstract][Full Text] [Related]
3. Whole-genome CRISPR screening identifies PI3K/AKT as a downstream component of the oncogenic GNAQ-focal adhesion kinase signaling circuitry. Arang N; Lubrano S; Rigiracciolo DC; Nachmanson D; Lippman SM; Mali P; Harismendy O; Gutkind JS J Biol Chem; 2023 Feb; 299(2):102866. PubMed ID: 36596361 [TBL] [Abstract][Full Text] [Related]
4. Synthetic Lethal Screens Reveal Cotargeting FAK and MEK as a Multimodal Precision Therapy for Paradis JS; Acosta M; Saddawi-Konefka R; Kishore A; Gomes F; Arang N; Tiago M; Coma S; Lubrano S; Wu X; Ford K; Day CP; Merlino G; Mali P; Pachter JA; Sato T; Aplin AE; Gutkind JS Clin Cancer Res; 2021 Jun; 27(11):3190-3200. PubMed ID: 33568347 [TBL] [Abstract][Full Text] [Related]
5. Mutant Gq/11 promote uveal melanoma tumorigenesis by activating YAP. Yu FX; Luo J; Mo JS; Liu G; Kim YC; Meng Z; Zhao L; Peyman G; Ouyang H; Jiang W; Zhao J; Chen X; Zhang L; Wang CY; Bastian BC; Zhang K; Guan KL Cancer Cell; 2014 Jun; 25(6):822-30. PubMed ID: 24882516 [TBL] [Abstract][Full Text] [Related]
6. Functional characterization of uveal melanoma oncogenes. Ma J; Weng L; Bastian BC; Chen X Oncogene; 2021 Jan; 40(4):806-820. PubMed ID: 33262460 [TBL] [Abstract][Full Text] [Related]
7. High-throughput chemogenetic drug screening reveals PKC-RhoA/PKN as a targetable signaling vulnerability in GNAQ-driven uveal melanoma. Arang N; Lubrano S; Ceribelli M; Rigiracciolo DC; Saddawi-Konefka R; Faraji F; Ramirez SI; Kim D; Tosto FA; Stevenson E; Zhou Y; Wang Z; Bogomolovas J; Molinolo AA; Swaney DL; Krogan NJ; Yang J; Coma S; Pachter JA; Aplin AE; Alessi DR; Thomas CJ; Gutkind JS Cell Rep Med; 2023 Nov; 4(11):101244. PubMed ID: 37858338 [TBL] [Abstract][Full Text] [Related]
8. Reciprocal positive regulation between BRD4 and YAP in GNAQ-mutant uveal melanoma cells confers sensitivity to BET inhibitors. Zhang GM; Huang SS; Ye LX; Liu XL; Shi WH; Ren ZL; Zhou RH; Zhang JJ; Pan JX; Liu SW; Yu L; Li YL Pharmacol Res; 2022 Oct; 184():106464. PubMed ID: 36162600 [TBL] [Abstract][Full Text] [Related]
9. Copper ionophore elesclomol selectively targets GNAQ/11-mutant uveal melanoma. Li Y; Yang J; Zhang Q; Xu S; Sun W; Ge S; Xu X; Jager MJ; Jia R; Zhang J; Fan X Oncogene; 2022 Jul; 41(27):3539-3553. PubMed ID: 35697803 [TBL] [Abstract][Full Text] [Related]
10. Combination small molecule MEK and PI3K inhibition enhances uveal melanoma cell death in a mutant GNAQ- and GNA11-dependent manner. Khalili JS; Yu X; Wang J; Hayes BC; Davies MA; Lizee G; Esmaeli B; Woodman SE Clin Cancer Res; 2012 Aug; 18(16):4345-55. PubMed ID: 22733540 [TBL] [Abstract][Full Text] [Related]
16. Prognostic impact of chromosomal aberrations and GNAQ, GNA11 and BAP1 mutations in uveal melanoma. Staby KM; Gravdal K; Mørk SJ; Heegaard S; Vintermyr OK; Krohn J Acta Ophthalmol; 2018 Feb; 96(1):31-38. PubMed ID: 28444874 [TBL] [Abstract][Full Text] [Related]
17. Palmitoylation of GNAQ/11 is critical for tumor cell proliferation and survival in GNAQ/11-mutant uveal melanoma. Zhang Y; Zhang B; Li Y; Dai Y; Li J; Li D; Xia Z; Zhang J; Liu P; Chen M; Jiao B; Ren R Front Med; 2022 Oct; 16(5):784-798. PubMed ID: 35997986 [TBL] [Abstract][Full Text] [Related]
18. ARF6 Is an Actionable Node that Orchestrates Oncogenic GNAQ Signaling in Uveal Melanoma. Yoo JH; Shi DS; Grossmann AH; Sorensen LK; Tong Z; Mleynek TM; Rogers A; Zhu W; Richards JR; Winter JM; Zhu J; Dunn C; Bajji A; Shenderovich M; Mueller AL; Woodman SE; Harbour JW; Thomas KR; Odelberg SJ; Ostanin K; Li DY Cancer Cell; 2016 Jun; 29(6):889-904. PubMed ID: 27265506 [TBL] [Abstract][Full Text] [Related]
19. The oncolytic virus H101 combined with GNAQ siRNA-mediated knockdown reduces uveal melanoma cell viability. Li Y; He J; Qiu C; Shang Q; Qian G; Fan X; Ge S; Jia R J Cell Biochem; 2019 Apr; 120(4):5766-5776. PubMed ID: 30320917 [TBL] [Abstract][Full Text] [Related]
20. Oncogenic G Protein GNAQ Induces Uveal Melanoma and Intravasation in Mice. Huang JL; Urtatiz O; Van Raamsdonk CD Cancer Res; 2015 Aug; 75(16):3384-97. PubMed ID: 26113083 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]